Article
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
International journal of cancer - 15 Oct 2022
Niger Monica, Nichetti Federico, Casadei-Gardini Andrea, Rizzato Mario Domenico, Pircher Chiara, Bini Marta, Franza Andrea, Rimini Margherita, Burgio Valentina, Sposetti Caterina, Fornaro Lorenzo, Rapposelli Ilario Giovanni, D'Amico Francesco Enrico, Aprile Giuseppe, Vivaldi Caterina, Frassineti Giovanni Luca, Milione Massimo, Leoncini Giuseppe, Cappetta Alessandro, Vasile Enrico, Fassan Matteo, Morano Federica, Perrone Federica, Tamborini Elena, Pruneri Giancarlo, Lonardi Sara, Mazzaferro Vincenzo, Pietrantonio Filippo, Di Bartolomeo Maria, de Braud Filippo
Abstract excerpt
Isocitrate dehydrogenase (IDH)1/2 mutations are the most frequent druggable alterations in intrahepatic cholangiocarcinoma (iCCA), reported in ~20% of cases. Preclinical evidence indicates that these mutations are associated with homologous recombination deficiency (HRD), which could be exploited as a target for platinum chemotherapy (ChT) and PARP inhibitors. However, the role of IDH1/2 mutations as surrogate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.